Journal for Immunotherapy of Cancer

Article	Citations
390 A global, molecular disease characterization initiative (MDCI) in oncology clinical trials	473
92 Single cell and spatial multiplex profiling of immune cell markers in FFPE tumor tissues using the novel RNAscope™ HiPlex v2 in situ hybridization assay	207
34 Selective infiltration of Antibody-Dependent Cellular Cytoxicity (ADCC) mediating immune cells in response to treatment in a human tumor histo-culture platform	184
62 Applying machine vision to empower preclinical development of cell engager and adoptive cell therapeutics in patient-derived organoid models of solid tumors	168
Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study	165
Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient during immunotherapy	163
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	161
Leveraging mRNA technology for antigen based immuno-oncology therapies	150
Frizzled-7-targeting antibody-derived bifunctional protein retargets NK cells against triple-negative breast cancer cells via MICA-NKG2D axis	141
214 SIRPα-deficient macrophages activate polyclonal tissue-resident cytotoxic CD8 T cells to eliminate irradiation-refractory non-small cell lung carcinoma	135
Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	133
65 Identification of frequently presented non-mutated tumor-specific immunogens for the development of both off-the-shelf and personalized vaccines without need for tumor biopsy	133
Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials	130
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial	127
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma	125
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors	122
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	121
Correction: Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future	117
90 Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers	115
Biomarkers for response to TIL therapy: a comprehensive review	115
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials	113
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy	109
GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies	108
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review	107
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes	107

Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment	104
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors	103
372 Association of tumor mutation burden (TMB) and genomic alterations (GA) with clinical outcomes in Chinese patients with advanced solid tumors treated with tislelizumab	99
67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer	96
229 CX3CR1 in exhausted CD8 T cell states	95
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	94
Skin mutation burden drives adaptive immunity and response to immunotherapy	94
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis	93
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	93
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab	92
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab	92
Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma	91
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma	89
Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models	88
Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy	87
Neuroblastoma: an ongoing cold front for cancer immunotherapy	86
Better understanding of ICI-induced cholangitis for better management	86
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report	85
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1	84
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden	84
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma	84
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment	82
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma	82
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma	82
Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions	82
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	80
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer	79
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer	78
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody	78
Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis	78
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series	77
Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia	77
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy	76
Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis	76
CARs are sharpening their weapons	74
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro	72
Comments on roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation	72
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials	71
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis	71
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck	69
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming	68
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study	68
Autophagic flux restoration enhances the antitumor efficacy of tumor infiltrating lymphocytes	68
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)	67
Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers	67
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells	66
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial	66
Cell-free DNA approaches for cancer early detection and interception	65
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis	65
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy	64

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release	64
Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment	64
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade	64
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	63
Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma	62
Emerging role of tumor-derived extracellular vesicles in T cell suppression and dysfunction in the tumor microenvironment	62
Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens	62
Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures	62
Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial	62
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multi	62
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors	62
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+TILs based onBRCA1/2mutation status in epithelial ovarian cancers	61
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial	61
Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab	61
Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma	59
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?	59
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors	59
Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes	57
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast c	57
Commentary on oncolytic viruses: past, present, and future	57
T-cell tolerant fraction as a predictor of immune-related adverse events	57
Saponin-based adjuvants enhance antigen cross-presentation in human CD11c+CD1c+CD5−CD163+conventional type 2 dendritic cells	57
Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate	56
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial	56
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	55
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity	55
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment	55
Helicobacter pyloriinfection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma	55
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma	55
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1	55
Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy	54
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma	54
BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma	54
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment	53
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy	52
Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry	52
NLRC5germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors	52
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial	52
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma	51
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma	51
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	51
Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study	51
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer	51
Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma	51
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemothera	51
Acknowledging and addressing real-world challenges to treating immune-related adverse events	51
Intratumoral and peritumoral radiomics of MRIs predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma	51
B cell c-Maf signaling promotes tumor progression in animal models of pancreatic cancer and melanoma	51
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	51
KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells	50
Escherichia coliadhesin protein-conjugated thermal responsive hybrid nanoparticles for photothermal and immunotherapy against cancer and its metastasis	50
Implication of99mTc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells	50
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors	50
CX-072 (pacmilimab), a Probody®PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study	50
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity	50
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity	50
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	50
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors	50
Mac Cheever (1944–2021): a tribute to a life of achievement and service	49
Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy	49
NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells	49
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade	49
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	49
Location of CD39+T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer	49
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response	48
Multimodal profiling of chordoma immunity reveals distinct immune contextures	48
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	47
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma	47
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma	47
CAR-T cell therapy in developing countries: how long should we wait?	47
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+T cell infiltration and functional transition	47
Impact ofHelicobacter pyloriinfection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors	47
Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway	46
Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway	46
BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1	46
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism	46
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia	46
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report	46
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus	46
High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells	46

Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by18F-BMS-986192 PET: pooled analysis of data from four solid tumor	46
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers	45
Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer	45
Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastoma	45
Local anesthetics elicit immune-dependent anticancer effects	45
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	45
iRECIST and atypical patterns of response to immuno-oncology drugs	44
The use of oncolytic virotherapy in the neoadjuvant setting	44
Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy	44
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	44
Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma	44
Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity	44
Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboringPOLEexonuclease domain mutation	43
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer	43
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	43
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	43
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer	43
Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer	43
Single-cell analysis reveals clonally expanded tumor-associated CD57+CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	43
Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer	43
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy	43
Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model	42
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	42
Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC	42
GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth	42
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy	42
Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report	42
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy	42
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer	42
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines	42
Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial	42
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL	42
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	42
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer	41
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities	41
Liquid biopsies coming of age: biology, emerging technologies, and clinical translation- An introduction to the JITC expert opinion special review series on liquid biopsies	41
EphA3 CAR T cells are effective against glioblastoma in preclinical models	41
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way	41
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	41
Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models	41
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	41
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	41
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases	41
SPI1+CD68+macrophages as a biomarker for gastric cancer metastasis: a rationale for combined antiangiogenic and immunotherapy strategies	40
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis	40
Correspondence on 'Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016' by Sussman et al	40
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	40
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	40
Preclinical model for evaluating human TCRs against chimeric syngeneic tumors	40
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treat	40
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors	40
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells	40
Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma	40
Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy	39
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release	39
Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis	39
228 Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity	39
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)	39
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study	39
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC	39
Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer	38
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas	38
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry	38
Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy	38
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	38
System analysis based on the cancer–immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma	38
CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors	38
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy	38
Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer	38
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies	38
Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	38
Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma	38
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial	37
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	37
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer	37
XCL1-secreting CEA CAR-T cells enhance endogenous CD8+T cell responses to tumor neoantigens to confer a long-term antitumor immunity	37
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden	37
FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer	37
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer	37
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	37
Intratumoral and peritumoral radiomics of MRI predicts pathologic complete response to neoadjuvant chemoimmunotherapy in patients with head and neck squamous cell carcinoma	37
ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasis	37
277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial	37
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy	37
Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects	37
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine	37
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers	36
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures	36
Correction: Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)	36
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)	36
Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab	36
iPSC-derived natural killer cells expressing the fcγr fusion CD64/16A can be armed with antibodies for multitumor antigen targeting	36
12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist	36
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	36
Correction: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	36